On September 13, 2021 BeiGene announced the FDA’s acceptance of its BLA for tislelizumab in esophageal squamous cell carcinoma (ESCC). While tislelizumab is already approved for five indications in China, this marks the first ex-China regulatory filing for the biologic. The BLA was filed in collaboration with Novartis and is…
